Current Studies
The “FORTRESS” Study (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1)
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF SAGE-217 PLUS AN ANTIDEPRESSANT VERSUS PLACEBO PLUS AN ANTIDEPRESSANT IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)
A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)
A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects with Dementia and Wandering Behaviors of Elopement and/or Getting Lost.
- For participants ages 18 to 65 experiencing fibromyalgia.
- Participants whose primary pain condition is fibromyalgia
- Willing to discuss stopping certain medications during the trial.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY COMPARING THE EFFICACY AND SAFETY OF SAGE-217 PLUS AN ANTIDEPRESSANT VERSUS PLACEBO PLUS AN ANTIDEPRESSANT IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
- For participants ages 18 to 65 experiencing a current episode of major depression.
- Study involves 11 check up visits over a 6 week period.
A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (RALLY)
- For participants ages 18 to 65 experiencing fibromyalgia.
- Participants whose primary pain condition is fibromyalgia
- Willing to discuss stopping certain medications during the trial.
A Study to Test the Effectiveness and Safety of Fremanezumab on Patients With Fibromyalgia
- For participants ages 18 to 75 experiencing fibromyalgia.
- Participants whose primary pain condition is fibromyalgia
- Willing to discuss stopping certain medications during the trial.
ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease (LIFT-AD)
- For participants ages 55 to 85 with Mild to Moderate Alzheimer's Dementia
- Reliable and capable support person/caregiver
A Phase 2a Combined Open-Label and Double-Blind, Placebo-Controlled Crossover Study Assessing the Effectiveness, Safety, and Tolerability of Oral Fasudil in Subjects with Dementia and Wandering Behaviors of Elopement and/or Getting Lost.
- For participants ages 50 to 90 with dementia of any kind
- Participant has wandering behaviors or gets lost. Examples might include trouble finding a familiar location, trying to leave, pacing, or entering areas that are off-limits.
- Reliable and capable support person/caregiver